法国绝经后骨质疏松女性使用肠溶利塞膦酸片治疗的成本效果
在法国绝经后骨质疏松女性中,采用马尔可夫微观模拟模型评估肠溶剂型利塞膦酸相比每周阿仑膦酸、仿制利塞膦酸和不治疗的一生成本(以2017年欧元计)每质量调整生命年(QALY)。结果显示,在所有模拟人群中,肠溶利塞膦酸在每QALY 60,000欧元阈值下均具成本效果;在75岁及以上女性中,相比对照策略甚至为优势策略(更多QALY、更低成本)。
要点
- 在BMD T评分≤-2.5且伴椎体骨折的女性中,肠溶利塞膦酸相比阿仑膦酸、仿制利塞膦酸和不治疗,每QALY增益成本低于20,000欧元。
- 在75岁及以上女性中,肠溶利塞膦酸相比阿仑膦酸、仿制利塞膦酸和不治疗为优势策略(更多QALY、更低成本)。
- 在所有模拟人群中,肠溶利塞膦酸在每QALY 60,000欧元阈值下相比对照均具成本效果。
核心结论
- 肠溶利塞膦酸相比每周阿仑膦酸、仿制利塞膦酸和不治疗,在法国绝经后骨质疏松女性中似乎是一种具有成本效果的策略。
研究设计与样本
- 采用先前验证的马尔可夫微观模拟模型,估算肠溶利塞膦酸相比每周阿仑膦酸、仿制利塞膦酸和不治疗的一生成本(以2017年欧元计)每QALY。
- 双膦酸盐疗效数据来自先前荟萃分析的合并数据,所有治疗选项均使用该数据;持续性数据(长达3年)来自一项大型澳大利亚纵向研究。
- 评估对象为60-80岁高风险女性,骨密度T评分≤-2.5和/或存在椎体骨折。
主要发现
- 在所有模拟人群中,肠溶利塞膦酸相比阿仑膦酸、仿制利塞膦酸和不治疗,在每QALY 60,000欧元阈值下均具成本效果。
- 在BMD T评分≤-2.5且伴椎体骨折的女性中,肠溶利塞膦酸相比阿仑膦酸、仿制利塞膦酸和不治疗,每QALY增益成本低于20,000欧元。
- 在75岁及以上女性中,肠溶利塞膦酸相比阿仑膦酸、仿制利塞膦酸和不治疗为优势策略(更多QALY、更低成本)。
关键数值与推荐
- 成本效果阈值:每QALY 60,000欧元。
- 在BMD T评分≤-2.5且伴椎体骨折的女性中,每QALY增益成本低于20,000欧元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France. INTRODUCTION: Gastro-resistant (GR) risedronate tablets are associated with improved persistence compared to common oral bisphosphonates but are slightly more expensive. This study assessed its cost-effectiveness compared to weekly alendronate and generic risedronate for the treatment of postmenopausal women with osteoporosis in France. METHODS: A previously validated Markov microsimulation model was used to estimate the lifetime costs (expressed in €2017) per quality-adjusted life-years (QALY) of GR risedronate compared with weekly alendronate, generic risedronate, and no treatment. Pooled efficacy data for bisphosphonates derived from a previous meta-analysis were used for all treatment options, and persistence data (up to 3 years) were obtained from a large Australian longitudinal study. Evaluation was done for high-risk women 60-80 years of age, with a bone mineral density (BMD) T-score ≤ - 2.5 and/or prevalent vertebral fractures. RESULTS: In all of the simulated populations, GR risedronate was cost-effective compared to alendronate, generic risedronate, and no treatment at a threshold of €60,000 per QALY gained. In women with a BMD T-score ≤ - 2.5 and prevalent vertebral fractures, the cost per QALY gained of GR risedronate compared to alendronate, generic risedronate, and no treatment falls below €20,000 per QALY gained. In women aged 75 years and older, GR risedronate was even shown to be dominant (more QALYs, less costs) compared to alendronate, generic risedronate, and no treatment. CONCLUSION: This study provides the first economic results about GR risedronate, suggesting that it represents a cost-effective strategy compared with weekly alendronate and generic risedronate for the treatment of postmenopausal women with osteoporosis in France.
引用
- Hiligsmann M, Reginster JY. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporos Int. 2019. PMID: 30701342. doi:10.1007/s00198-018-04821-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。